There has been a six-fold increase in the number of antibiotics being popped by Indians. This includes the retail sale of Carbapenems -- powerful class IV antibiotics, typically used as a "last resort" to treat serious infections caused by multi-drug resistant, gram-negative pathogens. Research by the Centre for Disease Dynamics, Economics and Policy, Washington DC, has found that retail sale of carbapenems increased six times -- from 0.21 units per million...

-The Telegraph The Centre today asked a panel of doctors to outline measures to improve drug approval procedures, three days after a parliamentary standing committee said India’s drug regulators had broken laws, ignoring the interests of patients. The panel announced by the Union health ministry has been asked to suggest steps to improve the procedural aspects of the Central Drugs Standards Control Organisation (CDSCO), the agency entrusted with approving medicines for sale...

The Government of India has formally launched the news Guidelines of the MGNAREGA based on the Mihir Shah Committee report. The news guidelines include many new works under conservation activities and it strengthens the hands of the village panchayats and gram sabhas. However, the list of works does not include the activities under the system of rice intensification (SRI) which encourages scientific method of paddy cultivation with better yield in...

A key finding in the report was that several multinational firms had launched drugs without conducting mandatory clinical trials or seeking expert medical opinion The health ministry has denied the presence of any systemic rot in the drug approval process and pharmaceutical firms have refuted charges of collusion after a report by a parliamentary panel pointed to regulatory lapses in clinical trials. The panel, which looked into the functioning of Central Drugs...

Having watched from the ringside for many years now, I have no doubt in advising that the steering wheel must be firmly grasped by the government and direction given to policies that should be stable for at least the medium term. This is crucial for the growth of Indian pharma, a $20-billion industry growing at an average of 12% considering both domestic and export arenas. Price control: The biggest and most...